GlassScriptPhysician profile
Tammy B Kelly
NPI 1215267349
$626.01
in general payments reported to CMS, 2019-2025
17 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $197 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.67 | 2023-2025 | |
| Exact Sciences Corporation | $92.87 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $58.96 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.86 | 2023 | Xifaxan, Trulance |
| Corcept Therapeutics | $46.03 | 2025 | Korlym |
| Novo Nordisk INC | $44.78 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $35.37 | 2025 | Breztri |
| Edwards Lifesciences Corporation | $31.23 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $30.83 | 2025 | Rexulti |
| Medtronic, INC. | $22.72 | 2024 | Intellis Adaptivestim |
| Viatris Specialty LLC | $22.25 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.37 | 2025 | Gvoke Hypopen |
| Vertex Pharmaceuticals Incorporated | $17.19 | 2025 | |
| Lundbeck LLC | $17.10 | 2025 | Rexulti |
| Mylan Specialty L.P. | $16.53 | 2024 | Yupelri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.51 | 2025 | Bexsero, Pediarix, Rotarix |
| Lilly USA, LLC | $13.74 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.